Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The efficacy of tissue factor -603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.

Experimental oncology - 1 Sept 2016

Eroğlu A, Ceylan G G, Ozturk E, Yalcin A, Yalcin B, Karasoy D

Abstract excerpt

UNLABELLED: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although factor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency in cancer patients remains poorly explored. Tissue factor (TF) is a major physiologic initiator of blood coagulation. This is the first study regarding the association of TF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Factor V
Share to Genotype
Share to Methylenetetrahydrofolate Reductase (NADPH2)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Polymorphism, Genetic

Share to Polymorphism, Restriction Fragment Length

Share to Thromboplastin

Share to Venous Thromboembolism

Source

Identifiers

PMID: 27685527

Genes

MTHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The efficacy of tissue factor -603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.PMID 27685527Read ↗

Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.Semantic proximity Read ↗

Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis.Semantic proximity Read ↗

No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients.Semantic proximity Read ↗

Prothrombotic genotypes and risk of venous thromboembolism in cancer.Semantic proximity Read ↗

Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).Semantic proximity Read ↗

Malignancies, prothrombotic mutations, and the risk of venous thrombosis.Semantic proximity Read ↗

Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.Semantic proximity Read ↗

Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients?Semantic proximity Read ↗

Thrombotic complications during cancer treatment in children.Semantic proximity Read ↗

Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma.Semantic proximity Read ↗

Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.